Dr. Fang Jianmin (房健民), aged 58, was appointed as our Director, chief executive officer and chief scientific officer on October 16, 2008, and redesignated as an executive Director on May 22, 2020. Dr. Fang is a co-founder of our Company and is primarily responsible for the overall management, business and strategy of our Group. Since inception, Dr. Fang has been the key driving force in our innovation and overseen our new drug research and development from discovery, target validation, CMC development, to clinical studies. He possesses more than 20 years of experience in the research and development of biopharmaceuticals. Dr. Fang also serves as director of RemeGen Medical Research (Shanghai) Co., Ltd., RemeGen Biosciences, Inc. and RemeGen Hong Kong Limited, our wholly-owned subsidiaries.
Dr. Fang obtained his doctorate degree in Biology from Dalhousie University in Canada in May 1998 and was a post-doctoral fellow focusing on cancer research at the Department of Surgery, Harvard Medical School/Boston Children’s Hospital from 1997 to 2000.
Dr. Fang was recognized as a Taishan Scholar (泰山学者) by the Shandong Provincial People’s Government (山东省人民政府) in March 2010. He has been a member of the scientific expert committee of the National Major Scientific and Technological Project for “Major Drug Innovations” of China (“重大新药创制”国家科技重大专项总体专家组) since December 2012 which overseen the nation’s drug innovation strategy. Dr. Fang is a professor of molecular medicine at School of Life Science and Technology at Tongji University in Shanghai, PRC. He is member of the Board of Directors of Chinese Pharmaceutical Association (中国药学会), vice chairman of Antibody Drug Division at China Medicinal Biotechnology Association (中国医药生物技术协会“单克隆抗体专业委员会”) and vice chairman of Drug Innovation Division at Chinese Pharmaceutical Innovation Research and Development Association (中国医药创新促进会药物研发专业委员会). He is the inventor of conbercept and owns more than 40 patents.